Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given a consensus recommendation of ...

PNC Financial Services Group Inc. trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 26.8 ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), it is important to understand the ownership structure of the business. We can see that institutions own the ...

The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

Rare Disease Day 2025 triggered a flurry of pharma marketing activity, with Arrowhead Pharmaceuticals, Zevra Therapeutics and a clutch of other drug developers publishing materials to mark the Feb ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

To address this gap, Arrowhead’s new initiatives aim to amplify patient voices, foster community, and provide accessible educational tools.